McKesson Corporation is acquiring Precision Medicine Group for $2.25 billion, significantly expanding its drug development and commercialisation capabilities.
The healthcare wholesaler, which ranks eighth on the Fortune 500 list, will fold privately held Precision Medicine Group into its oncology branch following regulatory approval.
The deal follows McKesson’s restructure last autumn, when the Texas-based firm announced a sharper focus on high-margin segments including biopharma and cancer care.
Founded in 2012, Maryland-based Precision Medicine Group offers clinical testing, complex trial design, biomarker identification, and commercialisation support across five labs in the US and Europe.
The company’s clinical trial work is heavily concentrated in oncology, making it a natural strategic fit for McKesson’s existing operations in that segment.
McKesson CEO Brian Tyler said the acquisition would “enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden out clinical services.”
The transaction adds Precision Medicine Group’s global clinical research organisation, biomarker intelligence, laboratory services, market access consulting, and commercialisation capabilities to McKesson’s healthcare platform.
Revenue in McKesson’s oncology and multispecialty division jumped 33% to $14.2 billion in the first quarter of fiscal 2026, fuelled by growth in services to healthcare providers and specialty distribution.
McKesson has also agreed to sell a minority stake in its medical-surgical solutions business to Apollo Funds for $1.25 billion, as it pursues an initial public offering for that unit.
Shares of McKesson were up 1.2% in early trading following the announcement, reflecting cautious optimism from investors about the strategic direction.
Leerink Partners analyst Michael Cherny noted the acquisition fits with McKesson’s current portfolio and is not a “bet-the-farm” transaction, given its value is equivalent to just over 2% of the company’s market capitalisation.
Cherny added that investors would want more clarity on how McKesson can help scale Precision and create synergies from the deal going forward.
J.P. Morgan analyst Lisa Gill said the tuck-in deal will likely strengthen McKesson’s biopharma offerings as the company continues reshaping its portfolio.
Precision Medicine Group CEO Margaret Keegan said joining McKesson would provide an opportunity to extend the company’s clinical and commercial capabilities to a wider group of customers and patients.
McKesson has not provided a specific timeline for when the transaction is expected to clear regulatory scrutiny and formally close.